AbbVie's Humira (adalimumab) reduces early tissue inflammation, rectal bleeding, and stool frequency in patients with ulcerative colitis, according to a post-hoc analysis of two Phase 3 trials. Findings were published in the study, "Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials," were published in the Journal of Crohn's and Colitis. Ulcerative colitis (UC) is an autoimmune disease characterized by inflammation of the lower gastrointestinal (GI) tract, including the colon (large intestine) and the rectum. It may start with mild symptoms that gradually worsen, with periods of remission in between. "The European Crohn’s and Colitis Organisation guidelines recommend anti-TNF-alpa [Humira] or vedolizumab [Entyvio] as first-line biologic therapy for treatment of active UC. The efficacy and safety of adalimumab (anti–TNF-alpa) for induction and maintenance of clinical remission in adult patients with moderately-to-severely active UC were demonstrated in two randomized, placebo-controlled clinical trials, ULTRA 1 and 2," the investigators wrote.